John Mann
General Practice · Dunn, NCNPI 1639118102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Avanir Pharmaceuticals, Inc. at 25.8% of the total. Reporting peaked in 2019 at $999 and has fallen 98.7% since, to $13 in 2023. Among general practice clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$519
- Amgen$332
- Novo Nordisk$262
- Novartis$153
- Sunovion Pharmaceuticals Inc.$103
- Lilly USA, LLC$97
- plus $544 from 13 others
What the payments were for
- Food & beverage$2,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 34 | $519 |
| Amgen | 12 | $332 |
| Novo Nordisk | 11 | $262 |
| Novartis | 6 | $153 |
| Sunovion Pharmaceuticals Inc. | 8 | $103 |
| Lilly USA, LLC | 4 | $97 |
| Boehringer Ingelheim | 6 | $94 |
| Sanofi-aventis U.S. LLC | 2 | $78 |
| Endogastric Solutions, Inc | 1 | $70 |
| AstraZeneca | 4 | $65 |
| GSK | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $45 |
| AbbVie(2 entities) | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $26 |
| Zealand Pharma US, Inc. | 2 | $25 |
| Forte Bio-pharma LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,010 in reported general payments places this provider in the 90th percentile of 2,924 general practice providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $54 | $6,72511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,924 general practice providers in North Carolina.
Other general practice in Dunn
- Matthew MillerCharlotte$937K
- James BarberDurham$768K
- Robert LoweCharlotte$615K
- Clifton CameronFayetteville$404K
- Leo HaydtHolly Springs$119K
- Andrew KellyGreensboro$115K
- Mark HymanGreensboro$95K
- Jesse ClarkWilmington$91K
- Adam HodgesAsheville$88K
- Edward WendaRaleigh$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.